[Addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection: efficiency and adverse events]

Rev Gastroenterol Peru. 2014 Oct-Dec;34(4):315-20.
[Article in Spanish]

Abstract

Objectives: To establish the efficiency and adverse effects of the addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection.

Material and methods: Double blind controlled experimental trial. The study population consisted of 54 patients with Helicobacter pylori infection: 29 were allocated to the experimental group, who received the usual triple plus bismuth subsalicylate therapy, and 24 received the triple therapy plus placebo.

Results: The average age was 47+-14.9 years, 66.7% of the patients were women. Both groups underwent the breath test: it was negative in 89.7% of the patients from the experimental group and 80% of the patients from the placebo group (p=0.319). The adverse events of both groups were: diarrhea (10.3% in the experimental group vs 16% in the placebo group; p=0.537), dark feces (37.9% in the experimental group vs 0% in the placebo group; p=0.001), abdominal pain (20.7% in the experimental group vs 52% in the placebo group; p=0.016). Nausea only were present in 3% of the patients of placebo group p=0.055).

Conclusions: The association of bismuth subsalicylate to the triple therapy scheme for the eradication of Helicobacter pylori was effective in 89.7% of patients, whereas 80% of efficiency in the experimental group.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Bismuth / therapeutic use*
  • Clarithromycin / therapeutic use
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori*
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / therapeutic use
  • Organometallic Compounds / therapeutic use*
  • Proton Pump Inhibitors / therapeutic use*
  • Salicylates / therapeutic use*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Organometallic Compounds
  • Proton Pump Inhibitors
  • Salicylates
  • bismuth subsalicylate
  • Amoxicillin
  • Clarithromycin
  • Omeprazole
  • Bismuth